Elvitegravir

CAS No. 697761-98-1

Elvitegravir( GS-9137, JTK-303 )

Catalog No. M15676 CAS No. 697761-98-1

Elvitegravir (GS-9137, JTK-303) is an HIV integrase inhibitor for HIV-1 IIIB, HIV-2 EHO and HIV-2 ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM in cell-free assays, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 45 In Stock
5MG 45 In Stock
10MG 75 In Stock
25MG 147 In Stock
50MG 277 In Stock
100MG 452 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Elvitegravir
  • Note
    Research use only, not for human use.
  • Brief Description
    Elvitegravir (GS-9137, JTK-303) is an HIV integrase inhibitor for HIV-1 IIIB, HIV-2 EHO and HIV-2 ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM in cell-free assays, respectively.
  • Description
    Elvitegravir (GS-9137, JTK-303) is an HIV integrase inhibitor for HIV-1 IIIB, HIV-2 EHO and HIV-2 ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM in cell-free assays, respectively.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    GS-9137, JTK-303
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV-1 IIIB| HIV-2 EHO| HIV-2 ROD
  • Research Area
    Infection
  • Indication
    ——

Chemical Information

  • CAS Number
    697761-98-1
  • Formula Weight
    447.88
  • Molecular Formula
    C23H23ClFNO5
  • Purity
    >98% (HPLC)
  • Solubility
    Ethanol: 35 mg/mL (78.14 mM); DMSO: 90 mg/mL (200.94 mM)
  • SMILES
    CC(C)[C@@H](CO)N1C=C(C(=O)C2=CC(=C(C=C21)OC)CC3=C(C(=CC=C3)Cl)F)C(=O)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Shimura K, et al. J Virol. 2008, 82(2), 764-774.
molnova catalog
related products
  • BMS-538203

    A chemical intermidate of BMS-626529, a HIV-1 attachment inhibitor that targets gp120,

  • BMS-986001

    A thymidine analogue nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-2 isolates from treatment-naive individuals with EC50 of 30-81 nM.

  • HIV-1 inhibitor 18A

    HIV-1 inhibitor 18A is a novel broad HIV-1 inhibitor that blocks envelope glycoprotein transitions critical for entry.